Stay updated on iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial
Sign up to get notified when there's something new on the iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial page.

Latest updates to the iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial page
- Check2 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe study record page now shows a 403 Forbidden error, replacing the previous content. This indicates that access to the page is blocked and the normal study details are not visible.SummaryDifference19%

- Check23 days agoChange DetectedThe page revision tag was updated from v3.6.6 to v3.7.0. This indicates a backend update to the page without changes to the displayed study information.SummaryDifference0.1%

- Check37 days agoChange DetectedThe page revision was updated from v3.6.5 to v3.6.6, indicating a minor maintenance update to the study page with no evident changes to study content.SummaryDifference0.1%

- Check58 days agoChange DetectedThe page revision was updated from v3.6.4 to v3.6.5, signaling a new build or update to the page content. This is a routine maintenance version change rather than a content change affecting study details.SummaryDifference0.1%

- Check73 days agoChange DetectedThe page's revision tag was updated from v3.6.3 to v3.6.4, indicating a new build of the page.SummaryDifference0.1%

Stay in the know with updates to iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial page.